A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
NCT07417306 on ClinicalTrials.gov · last registry update 2026-02-18
An unusually large phase 3: 912 participants, more than double the 424 typical for the stage. Due to report 30 August 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Change from baseline in Hemoglobin A1c (HbA1c). Sponsors move these dates routinely; any movement since this site started watching is listed below. mazdutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- NOT_YET_RECRUITING
- Phase
- P3
- Drug
- mazdutide
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Sponsor type
- Industry
- Enrollment
- 912
- Started
- 2026-03-27
- Primary completion
- 2027-08-30 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change from baseline in Hemoglobin A1c (HbA1c)
Conditions studied
Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the mazdutide page for this molecule’s full trial and approval history.